The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments

The ErbB2 receptor is a clinically validated cancer target whose internalization and trafficking mechanisms remain poorly understood. HSP90 inhibitors, such as geldanamycin (GA), have been developed to target the receptor to degradation or to modulate downstream signaling. Despite intense investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortese, Katia, Howes, Mark T., Lundmark, Richard, Tagliatti, Erica, Bagnato, Paola, Petrelli, Annalisa, Bono, Maria, McMahon, Harvey T., Parton, Robert G., Tacchetti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Cell Biology 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541960/
https://www.ncbi.nlm.nih.gov/pubmed/23154999
http://dx.doi.org/10.1091/mbc.E12-04-0282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541960/
https://www.ncbi.nlm.nih.gov/pubmed/23154999
http://dx.doi.org/10.1091/mbc.E12-04-0282

Ejemplares similares